Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.

× No keyword cloud information.

9 in total

1. Oral premalignancy: new methods of detection and treatment.

Authors: Ann Gillenwater; Vali Papadimitrakopoulou; Rebecca Richards-Kortum
Journal: Curr Oncol Rep Date: 2006-03 Impact factor: 5.075

2. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

Authors: Dong M Shin; Hongzheng Zhang; Nabil F Saba; Amy Y Chen; Sreenivas Nannapaneni; A R M Ruhul Amin; Susan Müller; Melinda Lewis; Gabriel Sica; Scott Kono; Johann C Brandes; William J Grist; Rachel Moreno-Williams; Jonathan J Beitler; Sufi M Thomas; Zhengjia Chen; Hyung Ju C Shin; Jennifer R Grandis; Fadlo R Khuri; Zhuo Georgia Chen
Journal: Clin Cancer Res Date: 2013-02-19 Impact factor: 12.531

3. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

Authors: Shibo Fu; Michael Rivera; Eric C Ko; Andrew G Sikora; Chien-Ting Chen; Ha Linh Vu; David Cannan; Samuel Eisenstein; Barry S Rosenstein; Julio Aguirre-Ghiso; Shu-Hsia Chen; Johnny Kao
Journal: J Cell Sci Ther Date: 2011-10-13

4. Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

Authors: Michiyuki Hakozaki; Hiroshi Hojo; Michiko Sato; Takahiro Tajino; Hitoshi Yamada; Shinichi Kikuchi; Masafumi Abe
Journal: Virchows Arch Date: 2009-11-18 Impact factor: 4.064

5. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors: Barbara J Gitlitz; Eric Bernstein; Edgardo S Santos; Greg A Otterson; Ginger Milne; Mary Syto; Francis Burrows; Sara Zaknoen
Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609

9. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling.

Authors: S Parida; I Pal; A Parekh; B Thakur; R Bharti; S Das; M Mandal
Journal: Cell Death Dis Date: 2016-03-24 Impact factor: 8.469

9 in total

Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.

1. Oral premalignancy: new methods of detection and treatment.

2. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.

3. Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.

4. Establishment and characterization of a novel human malignant peripheral nerve sheath tumor cell line, FMS-1, that overexpresses epidermal growth factor receptor and cyclooxygenase-2.

5. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Review 6. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.

7. Oral carcinogenesis and oral cancer chemoprevention: a review.

8. Understanding carcinogenesis for fighting oral cancer.

9. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling.